CLEVELAND, OH — In a move signaling both a maturation of its corporate identity and a bold step toward future growth, WTWH Media, the powerhouse parent company behind Drug Discovery & Development (DDD) and over 40 other prominent B2B media brands, officially announced its transformation into Arrowfly.
The rebranding, which took effect on July 13, 2026, marks the end of the WTWH Media era and the beginning of a new chapter for the Cleveland-based conglomerate. While the corporate entity has adopted the Arrowfly name, the company has emphasized that its portfolio of media brands—including DDD—will remain unchanged in name, editorial staffing, and core mission.
The Foundation of a Media Powerhouse
The transition to Arrowfly is not merely a cosmetic change but a strategic repositioning of a company that has spent years quietly building an empire across three critical economic sectors: engineering; healthcare and life sciences; and food, retail, and hospitality.
With a portfolio that encompasses over 45 industry-leading events and a vast digital presence, the company has established itself as an essential bridge between technical professionals and the complex markets they serve. For readers of Drug Discovery & Development, the rebrand serves as a reminder of the depth of the network supporting their industry. DDD sits at the center of the company’s healthcare and life sciences division, operating in synergy with sister brands that cover medical devices, health systems, senior care, and behavioral health.
This ecosystem allows for a cross-pollination of data and insights that is increasingly rare in modern B2B publishing. By uniting these verticals under the Arrowfly umbrella, the leadership team aims to leverage this interdisciplinary connectivity to provide even more robust intelligence for industry decision-makers.
Chronology of a Transformation
The journey toward Arrowfly has been marked by a deliberate, multi-year strategy of expansion and refinement.
- 2022: The Strategic Pivot. The company entered into a significant partnership with Mountaingate Capital. This private equity backing provided the financial impetus to accelerate the company’s growth, allowing for a series of strategic acquisitions that broadened its reach within the healthcare and life sciences sectors.
- 2025: Executive Transition. As the company scaled, it sought new leadership to guide its next phase. Matt Logan, a B2B media veteran with over 25 years of experience, was appointed CEO. His tenure brought a renewed focus on digital integration and the expansion of the company’s event portfolio.
- July 2026: The Launch of Arrowfly. Following eighteen months of internal planning, the company officially retired the WTWH Media brand. The rebrand was timed to coincide with a broader push to modernize the company’s digital infrastructure and expand its global footprint.
Understanding the "Why": A Vision for the Future
When asked about the impetus behind the name change, CEO Matt Logan emphasized the necessity of evolving alongside the industries the company covers.
"We built this company by earning the trust of professionals in industries where editorial authority matters," Logan stated in an official release. "The name is new, but the foundation is the same: editors who speak each industry’s language, events that connect buyers and sellers who would never meet otherwise, and communities that professionals rely on for the insight and intelligence they need to make real decisions."
The name "Arrowfly" was chosen to represent speed, precision, and forward momentum—qualities that the company claims are essential to navigating the fast-paced world of drug development, engineering, and healthcare technology. By shedding the legacy acronym of its founding, the company is positioning itself as a modern, unified entity capable of meeting the challenges of a digital-first media landscape.
Supporting Data: The Scale of the New Entity
To appreciate the weight of this rebrand, one must look at the scope of the Arrowfly operation. The company manages a digital footprint that attracts millions of industry professionals annually. Key metrics defining the current state of the organization include:
- Brand Diversity: Over 40 distinct B2B media brands, each maintaining independent editorial integrity while sharing a common corporate infrastructure.
- Event Impact: A portfolio of 45+ industry events. These aren’t just trade shows; they serve as critical nodes where the B2B ecosystem—including developers, manufacturers, and service providers—convenes to address supply chain, regulatory, and innovation hurdles.
- Sector Breadth: Operations span three primary "networks."
- The Engineering Network: Focusing on robotics, motion control, and design.
- The Healthcare/Life Sciences Network: Including Drug Discovery & Development, providing clinical and research-based intelligence.
- The Food, Retail, and Hospitality Network: Tracking consumer trends and operational efficiencies.
For the pharmaceutical sector, this breadth is a strategic advantage. In an era where drug discovery is increasingly reliant on robotics, advanced materials, and AI-driven data processing, the ability to pull expertise from the company’s engineering and life sciences divisions provides an editorial edge that specialized outlets cannot match.
Implications for the Drug Discovery Sector
What does this mean for the researchers, scientists, and pharma executives who rely on Drug Discovery & Development? The short answer is: continuity.
The editorial team, led by experts like Brian Buntz—who brings nearly two decades of experience in life sciences and technology—remains at the helm. The archives, which contain thousands of articles documenting the evolution of clinical trials, regulatory shifts, and breakthroughs in drug development, are fully preserved.
However, the rebrand implies a commitment to future-proofing. As the industry grapples with the integration of AI, machine learning, and advanced analytics, Arrowfly has signaled that it intends to invest further in these areas. For Buntz and his colleagues, the backing of a larger, unified corporate entity means more resources for deep-dive reporting, data-driven journalism, and the expansion of digital tools that help professionals parse the noise of an increasingly data-heavy industry.
Leadership Perspective: Maintaining the "Editorial Language"
A critical pillar of the Arrowfly philosophy is the retention of subject-matter expertise. Unlike mass-market media conglomerates that often generalize content, the company insists on hiring editors who possess deep, domain-specific knowledge.
Brian Buntz, whose career has spanned from UBM and Informa to his current role at the company, exemplifies this approach. His focus on the convergence of technology and healthcare—specifically his work on NLP, predictive analytics, and AI in the lab—reflects the broader goal of the organization: to provide not just news, but actionable intelligence.
"The industry needs more than headlines," notes an internal spokesperson for the company. "It needs context. By keeping our editorial teams specialized and empowered, we ensure that an Arrowfly brand remains a primary source of truth, regardless of the change in the company’s name."
Looking Ahead: The Path for Arrowfly
As Arrowfly moves into the latter half of 2026 and beyond, the focus will likely remain on integrating its vast network of events and digital media. The challenges facing B2B media are significant—shifting advertising models, the need for high-quality gated content, and the pressure to deliver measurable ROI for event attendees.
By consolidating its identity, Arrowfly is better positioned to market its holistic value proposition. For sponsors, it offers a single, powerful partner with access to decision-makers across the engineering and healthcare spectrum. For readers, it promises a stable, authoritative voice in an industry characterized by rapid change.
The rebrand to Arrowfly is, ultimately, a statement of confidence. It suggests that the company is no longer just a collection of acquired assets, but a unified force in the professional media landscape. Whether through its coverage of the next breakthrough in drug discovery or its facilitation of critical industry partnerships, Arrowfly is setting its sights on the next decade of growth, aiming to provide the intelligence that drives the future of global industry.
For more information regarding the transition or to explore the expanded network of brands, professionals are encouraged to visit arrowfly.com. As the industry continues to evolve, the firm promises to remain a constant, providing the, as they put it, "intelligence they need to make real decisions."
About the Author
